Nick Maskell

Prof. Nick Maskell

Academic Bristol Unit, University of Bristol, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Thorax
Verified
Journal Article
Open access
PDF file
CHClare Hooper
Clare Hooper
YLY C Gary Lee
Y C Gary Lee
NMNick Maskell
Nick Maskell
OGon behalf of the BTS Pleural Guideline Group
on behalf of the BTS Pleural Guideline Group
Pleural effusions occur as a result of increased fluid formation and/or reduced fluid resorption. The precise pathophysiology of fluid accumulation varies according to underlying aetiologies. As the differential diagnosis for a unilateral pleural effusion is wide, a systematic approach to investigation is necessary. The aim is to establish a diagnosis swiftly while minimising unnecessary invasive investigations and facilitating treatment, avoiding the need for repeated therapeutic aspirations when possible.

3 December 2020 in Thorax
Verified
Journal Article
Open access
PDF file
DADavid T Arnold
David T Arnold
FHFergus W Hamilton
Fergus W Hamilton
AMAlice Milne
Alice Milne
AMAnna J Morley
Anna J Morley
JVJason Viner
Jason Viner
SBShaney L Barratt
Shaney L Barratt
The longer-term consequences of SARS-CoV-2 infection are uncertain. Consecutive patients hospitalised with COVID-19 were prospectively recruited to this observational study (n=163). At 8–12 weeks postadmission, survivors were invited to a systematic clinical follow-up. Of 131 participants, 110 attended the follow-up clinic. Most (74%) had persistent symptoms (notably breathlessness and excessive fatigue) and limitations in reported physical ability. However, clinically significant abnormalities in chest radiograph, exercise tests, blood tests and spirometry were less frequent (35%), especially in patients not requiring supplementary oxygen during their acute infection (7%). Results suggest that a holistic approach focusing on rehabilitation and general well-being is paramount.

1 October 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DFDavid J Feller-Kopman
David J Feller-Kopman
CRChakravarthy B. Reddy
Chakravarthy B. Reddy
MDMalcolm M. DeCamp
Malcolm M. DeCamp
RDRebecca L. Diekemper
Rebecca L. Diekemper
MGMichael K. Gould
Michael K. Gould
ABAlex A. Balekian
Alex A. Balekian
Background: This Guideline, a collaborative effort from the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology, aims to provide evidence-based recommendations to guide contemporary management of patients with a malignant pleural effusion (MPE). Methods: A multidisciplinary panel developed seven questions using the PICO (Population, Intervention, Comparator, and Outcomes) format. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the Evidence to Decision framework was applied to each question. Recommendations were formulated, discussed, and approved by the entire panel. Results: The panel made weak recommendations in favor of: 1) using ultrasound to guide pleural interventions; 2) not performing pleural interventions in asymptomatic patients with MPE; 3) using either an indwelling pleural catheter (IPC) or chemical pleurodesis in symptomatic patients with MPE and suspected expandable lung; 4) performing large-volume thoracentesis to assess symptomatic response and lung expansion; 5) using either talc poudrage or talc slurry for chemical pleurodesis; 6) using IPC instead of chemical pleurodesis in patients with nonexpandable lung or failed pleurodesis; and 7) treating IPC-associated infections with antibiotics and not removing the catheter. Conclusions: These recommendations, based on the best available evidence, can guide management of patients with MPE and improve patient outcomes.

6 August 2014 in Thorax
Verified
Journal Article
Open access
PDF file
ACAmelia O Clive
Amelia O Clive
BKBrennan C Kahan
Brennan C Kahan
CHClare E Hooper
Clare E Hooper
RBRahul Bhatnagar
Rahul Bhatnagar
AMAnna J Morley
Anna J Morley
NMNick Maskell
Nick Maskell
Background Malignant pleural effusion (MPE) causes debilitating breathlessness and predicting survival is challenging. This study aimed to obtain contemporary data on survival by underlying tumour type in patients with MPE, identify prognostic indicators of overall survival and develop and validate a prognostic scoring system. Methods Three large international cohorts of patients with MPE were used to calculate survival by cell type (univariable Cox model). The prognostic value of 14 predefined variables was evaluated in the most complete data set (multivariable Cox model). A clinical prognostic scoring system was then developed and validated. Results Based on the results of the international data and the multivariable survival analysis, the LENT prognostic score (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group (ECOG) performance score (PS), neutrophil-to-lymphocyte ratio and tumour type) was developed and subsequently validated using an independent data set. Risk stratifying patients into low-risk, moderate-risk and high-risk groups gave median (IQR) survivals of 319 days (228–549; n=43), 130 days (47–467; n=129) and 44 days (22–77; n=31), respectively. Only 65% (20/31) of patients with a high-risk LENT score survived 1 month from diagnosis and just 3% (1/31) survived 6 months. Analysis of the area under the receiver operating curve revealed the LENT score to be superior at predicting survival compared with ECOG PS at 1 month (0.77 vs 0.66, p<0.01), 3 months (0.84 vs 0.75, p<0.01) and 6 months (0.85 vs 0.76, p<0.01). Conclusions The LENT scoring system is the first validated prognostic score in MPE, which predicts survival with significantly better accuracy than ECOG PS alone. This may aid clinical decision making in this diverse patient population.

5 April 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
RBRahul Bhatnagar
Rahul Bhatnagar
EKEmma K. Keenan
Emma K. Keenan
AMAnna J. Morley
Anna J. Morley
BKBrennan C. Kahan
Brennan C. Kahan
ASAndrew E. Stanton
Andrew E. Stanton
NMNick Maskell
Nick Maskell
Malignant pleural effusion affects more than 750,000 persons each year across Europe and the United States. Pleurodesis with the administration of talc in hospitalized patients is the most common treatment, but indwelling pleural catheters placed for drainage offer an ambulatory alternative. We examined whether talc administered through an indwelling pleural catheter was more effective at inducing pleurodesis than the use of an indwelling pleural catheter alone.

1 April 2014 in Chest
Verified
Journal Article
Open access
NRNajib Rahman
Najib Rahman
BKBrennan C. Kahan
Brennan C. Kahan
RMRobert F. Miller
Robert F. Miller
FGFergus V. Gleeson
Fergus V. Gleeson
ANAndrew Nunn
Andrew Nunn
NMNick Maskell
Nick Maskell
Pleural infection is associated with a high morbidity and mortality. Development of a validated clinical risk score at presentation to identify those at high risk of dying would enable patient triage and may help formulate early management strategies. A clinical risk score was derived based on data from patients entering the multicenter UK pleural infection trial (first Multicenter Intrapleural Sepsis Trial [MIST1], n=411). From 22 baseline clinical characteristics, model selection was undertaken to find variables predictive of poor clinical outcome. Outcomes were mortality at 3 months (primary), need for surgical intervention at 3 months, and time from randomization to discharge. The derived scoring system RAPID (renal, age, purulence, infection source, and dietary factors) was validated using patients enrolled in the subsequent MIST2 trial (n=191). Age, urea, albumin, hospital-acquired infection, and nonpurulence predicted poor outcome. Patients were stratified into low-risk (0-2), medium-risk (3-4), and high-risk (5-7) groups. Using the low-risk group as a reference, a RAPID score of 3 to 4 and >4 was associated with an OR of 24.4 (95% CI, 3.1-186.7; P=.002) and 192.4 (95% CI, 25.0-1480.4; P<.001), respectively, for death at 3 months. In the validation cohort (MIST2), a medium-risk RAPID score was nonsignificantly associated with mortality (OR, 3.2; 95% CI, 0.8-13.2; P=.11), and a high-risk score was associated with increased mortality (OR, 14.1; 95% CI, 3.5-56.8; P<.001). Hospitalization duration was associated with increasing RAPID score (score 0-2: median duration=7, interquartile range 6-13; score>5: median duration=15, interquartile range 9-28, P=.08). The RAPID score may permit risk stratification of patients with pleural infection at presentation.